Sitagliptin (Januvia) for the treatment of patients with type 2 diabetes

被引：0
作者：
Whitley, Heather P. [1 ]
机构：
[1] Auburn Univ, Harrison Sch Pharm, Tuscaloosa, AL USA
[2] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA
来源：
AMERICAN FAMILY PHYSICIAN | 2007年 / 76卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：861 / 862
页数：2
相关论文
共 5 条
[1]   Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].
Aschner, Pablo ;
Kipnes, Mark S. ;
Lunceford, Jared K. ;
Sanchez, Matilde ;
Mickel, Carolyn ;
Williams-Herman, Debora E. .
DIABETES CARE, 2006, 29 (12) :2632-2637
[2]   Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].
Charbonnel, Bernard ;
Karasik, Avraham ;
Liu, Ji ;
Wu, Mei ;
Meininger, Gary .
DIABETES CARE, 2006, 29 (12) :2638-2643
[3]  
*MERCK CO INC, 2006, JAN TABL
[4]  
*MERCK CO INC, 2007, JAN TABL
[5]   Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus [J].
Raz, I. ;
Hanefeld, M. ;
Xu, L. ;
Caria, C. ;
Williams-Herman, D. ;
Khatami, H. .
DIABETOLOGIA, 2006, 49 (11) :2564-2571
1